Abstract
Novel dialkoxypyrid-2-ylalkyl-1,3-dihydro-2H-imidazol-2-one derivatives are claimed for the treatment of atopic and asthmatic diseases. The claimed compounds are selective PDE4 inhibitors that are shown to inhibit PDE4B and are indicated to be useful in the treatment of dermatological diseases such as psoriasis and atopic dermatitis.